{"pmid":32307298,"title":"Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis.","text":["Severe cerebral involvement in adult-onset hemophagocytic lymphohistiocytosis.","The diagnosis of hemophagocytic lymphohistiocytosis (HLH) with cerebral involvement is challenging given the rarity of HLH and its resemblance to the much more common severe sepsis. Timely diagnosis and treatment may be lifesaving. We report two cases demonstrating different and rare forms of severe brain involvement in adult patients with HLH: acute necrotizing encephalopathy, and diffuse hemorrhagic disease due to disseminated intravascular coagulation. Severe HLH with brain involvement in adults is rare. HLH with cerebral involvement should be considered in patients presenting with severe systemic inflammatory response syndrome (SIRS) but negative cultures and unusual or unexpectedly severe clinical and/or radiologic signs of cerebral dysfunction. Similar brain injury may occur in patients with cytokine storm syndrome due to COVID-19. BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) presents with fevers, rash, organomegaly, cytopenia, and increased triglycerides and ferritin (Ramos-Casals et al., 2014) [1]. Neurologic abnormalities are reported in about one-third of patients (Cai et al., 2017), including a few cases of acute necrotizing encephalopathy (ANE) (Xiujuan et al., 2015). Coagulation abnormalities are frequent in HLH patients (Valade et al., 2015). OBJECTIVE: To raise awareness about the importance of early diagnosis and treatment of HLH with neurological involvement to prevent serious complications and demise.","J Clin Neurosci","Radmanesh, Farid","Rodriguez-Pla, Alicia","Pincus, Michael D","Burns, Joseph D","32307298"],"abstract":["The diagnosis of hemophagocytic lymphohistiocytosis (HLH) with cerebral involvement is challenging given the rarity of HLH and its resemblance to the much more common severe sepsis. Timely diagnosis and treatment may be lifesaving. We report two cases demonstrating different and rare forms of severe brain involvement in adult patients with HLH: acute necrotizing encephalopathy, and diffuse hemorrhagic disease due to disseminated intravascular coagulation. Severe HLH with brain involvement in adults is rare. HLH with cerebral involvement should be considered in patients presenting with severe systemic inflammatory response syndrome (SIRS) but negative cultures and unusual or unexpectedly severe clinical and/or radiologic signs of cerebral dysfunction. Similar brain injury may occur in patients with cytokine storm syndrome due to COVID-19. BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) presents with fevers, rash, organomegaly, cytopenia, and increased triglycerides and ferritin (Ramos-Casals et al., 2014) [1]. Neurologic abnormalities are reported in about one-third of patients (Cai et al., 2017), including a few cases of acute necrotizing encephalopathy (ANE) (Xiujuan et al., 2015). Coagulation abnormalities are frequent in HLH patients (Valade et al., 2015). OBJECTIVE: To raise awareness about the importance of early diagnosis and treatment of HLH with neurological involvement to prevent serious complications and demise."],"journal":"J Clin Neurosci","authors":["Radmanesh, Farid","Rodriguez-Pla, Alicia","Pincus, Michael D","Burns, Joseph D"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307298","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jocn.2020.04.054","keywords":["acute necrotizing encephalopathy","adult onset still's disease","diffuse hemorrhagic encephalopathy","disseminated intravascular coagulation","hemophagocytic syndrome"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["organomegaly","cytopenia"],"e_drugs":["Triglycerides"],"_version_":1664632501560147968,"score":8.518259,"similar":[{"pmid":32277367,"title":"Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","text":["Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.","The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.","Clin Rheumatol","Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena","32277367"],"abstract":["The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points* Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.* Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.* Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice."],"journal":"Clin Rheumatol","authors":["Misra, Durga Prasanna","Agarwal, Vikas","Gasparyan, Armen Yuri","Zimba, Olena"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277367","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s10067-020-05073-9","keywords":["covid-19","epidemiology","hydroxychloroquine","hypothesis","immunity","pathogenesis","vaccines","vitamin d"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["thrombocytopenia","Cytokine","myocarditis","leucopenia","lymphopenia","thrombocytopenia"],"e_drugs":["Ibuprofen","tocilizumab","remdesivir","lopinavir-ritonavir drug combination","favipiravir","Chloroquine","Hydroxychloroquine"],"_version_":1664636943925772288,"score":406.91632},{"pmid":32251717,"title":"Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome.","text":["Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome.","Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. We provide a model for the classification of MAS to stratify the MAS-like presentation in COVID-19 pneumonia and explore the complexities of discerning ARDS from MAS. We describe the potential impact of viral load and therapy timing towards improving the outcome of IL-6 antagonism and other immunomodulatory therapies.","Autoimmun Rev","McGonagle, Dennis","Sharif, Kassem","O'Regan, Anthony","Bridgewood, Charlie","32251717"],"abstract":["Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. We provide a model for the classification of MAS to stratify the MAS-like presentation in COVID-19 pneumonia and explore the complexities of discerning ARDS from MAS. We describe the potential impact of viral load and therapy timing towards improving the outcome of IL-6 antagonism and other immunomodulatory therapies."],"journal":"Autoimmun Rev","authors":["McGonagle, Dennis","Sharif, Kassem","O'Regan, Anthony","Bridgewood, Charlie"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251717","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.autrev.2020.102537","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663352136284504064,"score":353.7515},{"pmid":32267081,"title":"Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.","text":["Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome.","OBJECTIVE: To report the benefit of a therapeutic approach consisting of intravenous continuous anakinra (recombinant human interleukin-1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS). METHODS: A retrospective chart review of five patients treated at Regions Hospital from 2016-2019. Demographic, clinical, laboratory characteristics and outcomes were recorded. RESULTS: Continuous IV anakinra infusions up to 2400 mg/day resulted in rapid serologic, then clinical response in 4/5 severely ill patients who were refractory to all other therapies including subcutaneous anakinra. Subsequently, 3/5 have been maintained on anakinra or canakinumab with no recurrence of MAS. CONCLUSION: Continuous infusion of IV anakinra may result in rapid serologic and subsequent clinical improvement in adult patients with MAS. This method for treating cytokine storm should be considered in the current COVID-19 pandemic in the subgroup of patients with severe disease that have a cytokine storm presentation.","ACR Open Rheumatol","Adam Monteagudo, Luke","Boothby, Aaron","Gertner, Elie","32267081"],"abstract":["OBJECTIVE: To report the benefit of a therapeutic approach consisting of intravenous continuous anakinra (recombinant human interleukin-1 receptor antagonist) infusions in treating severely ill adult patients with secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS). METHODS: A retrospective chart review of five patients treated at Regions Hospital from 2016-2019. Demographic, clinical, laboratory characteristics and outcomes were recorded. RESULTS: Continuous IV anakinra infusions up to 2400 mg/day resulted in rapid serologic, then clinical response in 4/5 severely ill patients who were refractory to all other therapies including subcutaneous anakinra. Subsequently, 3/5 have been maintained on anakinra or canakinumab with no recurrence of MAS. CONCLUSION: Continuous infusion of IV anakinra may result in rapid serologic and subsequent clinical improvement in adult patients with MAS. This method for treating cytokine storm should be considered in the current COVID-19 pandemic in the subgroup of patients with severe disease that have a cytokine storm presentation."],"journal":"ACR Open Rheumatol","authors":["Adam Monteagudo, Luke","Boothby, Aaron","Gertner, Elie"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267081","week":"202015|Apr 06 - Apr 12","doi":"10.1002/acr2.11135","keywords":["anakinra","inflammation","macrophase activation syndrome"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664637636112809984,"score":227.4746},{"pmid":32219357,"title":"Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).","text":["Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).","Importance: Virus infection has been widely described as one of the most common causes of myocarditis. However, less is known about the cardiac involvement as a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objective: To describe the presentation of acute myocardial inflammation in a patient with coronavirus disease 2019 (COVID-19) who recovered from the influenzalike syndrome and developed fatigue and signs and symptoms of heart failure a week after upper respiratory tract symptoms. Design, Setting, and Participant: This case report describes an otherwise healthy 53-year-old woman who tested positive for COVID-19 and was admitted to the cardiac care unit in March 2020 for acute myopericarditis with systolic dysfunction, confirmed on cardiac magnetic resonance imaging, the week after onset of fever and dry cough due to COVID-19. The patient did not show any respiratory involvement during the clinical course. Exposure: Cardiac involvement with COVID-19. Main Outcomes and Measures: Detection of cardiac involvement with an increase in levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T, echocardiography changes, and diffuse biventricular myocardial edema and late gadolinium enhancement on cardiac magnetic resonance imaging. Results: An otherwise healthy 53-year-old white woman presented to the emergency department with severe fatigue. She described fever and dry cough the week before. She was afebrile but hypotensive; electrocardiography showed diffuse ST elevation, and elevated high-sensitivity troponin T and NT-proBNP levels were detected. Findings on chest radiography were normal. There was no evidence of obstructive coronary disease on coronary angiography. Based on the COVID-19 outbreak, a nasopharyngeal swab was performed, with a positive result for SARS-CoV-2 on real-time reverse transcriptase-polymerase chain reaction assay. Cardiac magnetic resonance imaging showed increased wall thickness with diffuse biventricular hypokinesis, especially in the apical segments, and severe left ventricular dysfunction (left ventricular ejection fraction of 35%). Short tau inversion recovery and T2-mapping sequences showed marked biventricular myocardial interstitial edema, and there was also diffuse late gadolinium enhancement involving the entire biventricular wall. There was a circumferential pericardial effusion that was most notable around the right cardiac chambers. These findings were all consistent with acute myopericarditis. She was treated with dobutamine, antiviral drugs (lopinavir/ritonavir), steroids, chloroquine, and medical treatment for heart failure, with progressive clinical and instrumental stabilization. Conclusions and Relevance: This case highlights cardiac involvement as a complication associated with COVID-19, even without symptoms and signs of interstitial pneumonia.","JAMA Cardiol","Inciardi, Riccardo M","Lupi, Laura","Zaccone, Gregorio","Italia, Leonardo","Raffo, Michela","Tomasoni, Daniela","Cani, Dario S","Cerini, Manuel","Farina, Davide","Gavazzi, Emanuele","Maroldi, Roberto","Adamo, Marianna","Ammirati, Enrico","Sinagra, Gianfranco","Lombardi, Carlo M","Metra, Marco","32219357"],"abstract":["Importance: Virus infection has been widely described as one of the most common causes of myocarditis. However, less is known about the cardiac involvement as a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Objective: To describe the presentation of acute myocardial inflammation in a patient with coronavirus disease 2019 (COVID-19) who recovered from the influenzalike syndrome and developed fatigue and signs and symptoms of heart failure a week after upper respiratory tract symptoms. Design, Setting, and Participant: This case report describes an otherwise healthy 53-year-old woman who tested positive for COVID-19 and was admitted to the cardiac care unit in March 2020 for acute myopericarditis with systolic dysfunction, confirmed on cardiac magnetic resonance imaging, the week after onset of fever and dry cough due to COVID-19. The patient did not show any respiratory involvement during the clinical course. Exposure: Cardiac involvement with COVID-19. Main Outcomes and Measures: Detection of cardiac involvement with an increase in levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T, echocardiography changes, and diffuse biventricular myocardial edema and late gadolinium enhancement on cardiac magnetic resonance imaging. Results: An otherwise healthy 53-year-old white woman presented to the emergency department with severe fatigue. She described fever and dry cough the week before. She was afebrile but hypotensive; electrocardiography showed diffuse ST elevation, and elevated high-sensitivity troponin T and NT-proBNP levels were detected. Findings on chest radiography were normal. There was no evidence of obstructive coronary disease on coronary angiography. Based on the COVID-19 outbreak, a nasopharyngeal swab was performed, with a positive result for SARS-CoV-2 on real-time reverse transcriptase-polymerase chain reaction assay. Cardiac magnetic resonance imaging showed increased wall thickness with diffuse biventricular hypokinesis, especially in the apical segments, and severe left ventricular dysfunction (left ventricular ejection fraction of 35%). Short tau inversion recovery and T2-mapping sequences showed marked biventricular myocardial interstitial edema, and there was also diffuse late gadolinium enhancement involving the entire biventricular wall. There was a circumferential pericardial effusion that was most notable around the right cardiac chambers. These findings were all consistent with acute myopericarditis. She was treated with dobutamine, antiviral drugs (lopinavir/ritonavir), steroids, chloroquine, and medical treatment for heart failure, with progressive clinical and instrumental stabilization. Conclusions and Relevance: This case highlights cardiac involvement as a complication associated with COVID-19, even without symptoms and signs of interstitial pneumonia."],"journal":"JAMA Cardiol","authors":["Inciardi, Riccardo M","Lupi, Laura","Zaccone, Gregorio","Italia, Leonardo","Raffo, Michela","Tomasoni, Daniela","Cani, Dario S","Cerini, Manuel","Farina, Davide","Gavazzi, Emanuele","Maroldi, Roberto","Adamo, Marianna","Ammirati, Enrico","Sinagra, Gianfranco","Lombardi, Carlo M","Metra, Marco"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219357","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jamacardio.2020.1096","source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["Peptides","lopinavir-ritonavir drug combination","Dobutamine","Gadolinium","Steroids","Chloroquine"],"_version_":1664638743008509952,"score":206.60352},{"pmid":32293714,"title":"Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019.","text":["Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019.","There has been a global outbreak of coronavirus disease 2019 (COVID-19) since December 2019. In clinical practice, not only fever and respiratory tract symptoms but also multiple organ symptoms are observed in patients diagnosed with COVID-19. Herein, we report a rare case of a patient diagnosed with COVID-19 who manifested with concomitant neurological symptoms. The patient developed fever and respiratory symptoms at disease onset, followed by muscle soreness, and subsequently altered consciousness and psychiatric symptoms, with positive signs based on neurological examination. The patient tested positive for the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) nucleic acid (throat swab). Further, chest computed tomography (CT) revealed typical COVID-19 findings, and head CT did not reveal significant abnormalities. The patient recovered after treatment and was discharged. This rare case indicates that SARS-CoV-2 can invade the central nervous system, thus causing neurological symptoms and signs. This article is protected by copyright. All rights reserved.","J Med Virol","Yin, Rong","Feng, Wei","Wang, Tonghui","Chen, Gang","Wu, Tao","Chen, Dongrui","Lv, Tangfeng","Xiang, Dawei","32293714"],"abstract":["There has been a global outbreak of coronavirus disease 2019 (COVID-19) since December 2019. In clinical practice, not only fever and respiratory tract symptoms but also multiple organ symptoms are observed in patients diagnosed with COVID-19. Herein, we report a rare case of a patient diagnosed with COVID-19 who manifested with concomitant neurological symptoms. The patient developed fever and respiratory symptoms at disease onset, followed by muscle soreness, and subsequently altered consciousness and psychiatric symptoms, with positive signs based on neurological examination. The patient tested positive for the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) nucleic acid (throat swab). Further, chest computed tomography (CT) revealed typical COVID-19 findings, and head CT did not reveal significant abnormalities. The patient recovered after treatment and was discharged. This rare case indicates that SARS-CoV-2 can invade the central nervous system, thus causing neurological symptoms and signs. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yin, Rong","Feng, Wei","Wang, Tonghui","Chen, Gang","Wu, Tao","Chen, Dongrui","Lv, Tangfeng","Xiang, Dawei"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293714","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25888","keywords":["covid-19","meningitis","neurological symptoms"],"source":"PubMed","topics":["NONE","Case Report"],"weight":1,"_version_":1664636192529842176,"score":156.85556}]}